Xuxing Chen, Ph.D. Dr. Chen founded Euregen Biopharma and has served as the Chief Executive Officer since its inception in May 2020. Previously, Dr. Chen served as the Senior Scientist and Associate Director at Haihe Pharmaceuticals, where he led the discovery and preclinical development of the EZH1/2 dual inhibitor, HH2853, which is a clinical stage candidate. He is a co-inventor of more than 10 patents and patent applications, and also a co-author of 9 scientific publications. Dr. Chen received his Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences. He earned his B.Sc. from Tongji Medical College of Huazhong University of Science & Technology.